<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>CNVI.V</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<h1
id="conavi-medical-corp.-tsxv-cnvi-mda-summary-for-the-three-and-nine-months-ended-june-30-2025">Conavi
Medical Corp. (TSXV: CNVI) — MD&amp;A summary for the three and nine
months ended June 30, 2025</h1>
<h2 id="business-summary">Business summary</h2>
<ul>
<li>Developer of the Novasight Hybrid intravascular imaging system
combining IVUS and OCT for simultaneous, co-registered coronary imaging;
regulatory clearances in the US (FDA 510(k)), Canada, China (NMPA), and
Japan.</li>
<li>Focused on completing and commercializing next‑generation Novasight
3.0 (higher image quality, improved workflow/ease-of-use, better
catheter deliverability, and scalable manufacturing).</li>
<li>Multi-pronged revenue model: disposable catheter sales (consoles
typically placed at no charge), technology transfer/licensing and
components to China partner EOM, with future royalties from EOM’s
domestic system.</li>
<li>IP position includes 10 patent families (58 issued patents) covering
hybrid imaging core technologies; core U.S. patent family expiring 2030
(earlier in some jurisdictions); exclusive license from Sunnybrook with
sales-based royalties.</li>
</ul>
<h2 id="recent-developments">Recent developments</h2>
<ul>
<li>Closed reverse takeover of Titan Medical; name changed to Conavi
Medical Corp.; began trading on TSXV as “CNVI” (Oct 2024) and uplisted
to OTCQB (Mar 2025).</li>
<li>Financings: US$7.7M subscription receipts (Oct 2024) and C$20.0M
public offering (Apr 23, 2025).</li>
<li>China: EOM received NMPA approval for its domestic Novasight Hybrid
system (Dec 2024), triggering the fourth and final milestone payment to
Conavi; royalties to commence post‑launch.</li>
<li>Novasight 3.0 program: design freeze (Jan 2025), console DVT
complete (May 2025), catheter and system-level DVT and ECT completed
(Aug 2025); two successful preclinical (porcine) KOL validations in July
2025; FDA 510(k) submission targeted for late Q3 2025; U.S. launch
targeted 1H 2026.</li>
<li>Clinical/market momentum: 2025 ACC/AHA Class 1A guideline endorsing
intravascular imaging in specific PCI cases; peer-reviewed case report
highlighting hybrid IVUS/OCT benefits published July 2025.</li>
</ul>
<h2 id="key-issues">Key issues</h2>
<ul>
<li>Liquidity/going concern: cash of $11.3M (Jun 30, 2025) with negative
operating cash flow; additional financing likely required to complete
transfer to production (~$6.1M est. remaining) and support launch.</li>
<li>Debt covenants/refinance: ~$15.4M senior secured Japan Lifeline
facility (matures Apr 2027) requires 50% of annual positive operating
cash flow for repayment and “commercially reasonable efforts” to
refinance by Dec 1, 2025; secured by substantially all assets including
IP.</li>
<li>Execution risk: on-time FDA clearance, transfer to outsourced
production, scaling supply chain, and achieving targeted gross margins
for catheters and systems.</li>
<li>China concentration/contractual exposure: long‑term EOM distribution
and TTLA agreements include price reductions, minimum royalties, and
significant termination/repurchase obligations in certain
scenarios.</li>
<li>Non-cash P&amp;L volatility: warrant liability fair value, prior
convertible note fair value changes, and listing expense impacted
reported losses; limited product revenue and inventory provisions have
pressured gross margins.</li>
</ul>
<h2
id="consolidated-financial-summary-cad-000s-except-per-share-amounts">Consolidated
financial summary (CAD ‘000s, except per-share amounts)</h2>
<table>
<colgroup>
<col style="width: 32%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 5%" />
<col style="width: 6%" />
<col style="width: 6%" />
<col style="width: 6%" />
<col style="width: 6%" />
</colgroup>
<thead>
<tr>
<th>Metric (CAD ‘000s)</th>
<th style="text-align: right;">Q3-2025</th>
<th style="text-align: right;">Q2-2025</th>
<th style="text-align: right;">Q1-2025</th>
<th style="text-align: right;">Q4-2024</th>
<th style="text-align: right;">Q3-2024</th>
<th style="text-align: right;">Q2-2024</th>
<th style="text-align: right;">Q1-2024</th>
<th style="text-align: right;">Q4-2023</th>
<th style="text-align: right;">3M Jun-25</th>
<th style="text-align: right;">3M Jun-24</th>
<th style="text-align: right;">9M Jun-25</th>
<th style="text-align: right;">9M Jun-24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licensing &amp; R&amp;D services revenue</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">8,392</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">1,954</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">8,518</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>Product revenue</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">(5)</td>
<td style="text-align: right;">242</td>
<td style="text-align: right;">447</td>
<td style="text-align: right;">367</td>
<td style="text-align: right;">555</td>
<td style="text-align: right;">657</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">367</td>
<td style="text-align: right;">237</td>
<td style="text-align: right;">1,579</td>
</tr>
<tr>
<td>Total revenue</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">58</td>
<td style="text-align: right;">8,634</td>
<td style="text-align: right;">481</td>
<td style="text-align: right;">401</td>
<td style="text-align: right;">589</td>
<td style="text-align: right;">691</td>
<td style="text-align: right;">1,962</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">401</td>
<td style="text-align: right;">8,755</td>
<td style="text-align: right;">1,680</td>
</tr>
<tr>
<td>Cost of sales</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">(87)</td>
<td style="text-align: right;">1,548</td>
<td style="text-align: right;">445</td>
<td style="text-align: right;">459</td>
<td style="text-align: right;">613</td>
<td style="text-align: right;">591</td>
<td style="text-align: right;">585</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">459</td>
<td style="text-align: right;">1,462</td>
<td style="text-align: right;">1,663</td>
</tr>
<tr>
<td>Gross profit (loss)</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">145</td>
<td style="text-align: right;">7,086</td>
<td style="text-align: right;">36</td>
<td style="text-align: right;">(58)</td>
<td style="text-align: right;">(24)</td>
<td style="text-align: right;">100</td>
<td style="text-align: right;">1,377</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">(58)</td>
<td style="text-align: right;">7,293</td>
<td style="text-align: right;">17</td>
</tr>
<tr>
<td>Operating expenses</td>
<td style="text-align: right;">4,691</td>
<td style="text-align: right;">5,552</td>
<td style="text-align: right;">6,817</td>
<td style="text-align: right;">6,258</td>
<td style="text-align: right;">8,838</td>
<td style="text-align: right;">5,989</td>
<td style="text-align: right;">5,201</td>
<td style="text-align: right;">5,971</td>
<td style="text-align: right;">4,691</td>
<td style="text-align: right;">8,838</td>
<td style="text-align: right;">17,060</td>
<td style="text-align: right;">20,028</td>
</tr>
<tr>
<td>Operating income (loss) [EBIT]</td>
<td style="text-align: right;">(4,629)</td>
<td style="text-align: right;">(5,407)</td>
<td style="text-align: right;">269</td>
<td style="text-align: right;">(6,222)</td>
<td style="text-align: right;">(8,896)</td>
<td style="text-align: right;">(6,013)</td>
<td style="text-align: right;">(5,101)</td>
<td style="text-align: right;">(4,594)</td>
<td style="text-align: right;">(4,629)</td>
<td style="text-align: right;">(8,896)</td>
<td style="text-align: right;">(9,767)</td>
<td style="text-align: right;">(20,011)</td>
</tr>
<tr>
<td>Depreciation &amp; amortization</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">203</td>
<td style="text-align: right;">222</td>
<td style="text-align: right;">613</td>
<td style="text-align: right;">747</td>
</tr>
<tr>
<td>EBITDA</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">(4,426)</td>
<td style="text-align: right;">(8,674)</td>
<td style="text-align: right;">(9,154)</td>
<td style="text-align: right;">(19,264)</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
</tr>
<tr>
<td>Net finance costs (expense)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">124</td>
<td style="text-align: right;">1,474</td>
<td style="text-align: right;">11,542</td>
<td style="text-align: right;">4,859</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td style="text-align: right;">(3,561)</td>
<td style="text-align: right;">(3,125)</td>
<td style="text-align: right;">(7,035)</td>
<td style="text-align: right;">(16,087)</td>
<td style="text-align: right;">(13,028)</td>
<td style="text-align: right;">(7,109)</td>
<td style="text-align: right;">(7,389)</td>
<td style="text-align: right;">(7,057)</td>
<td style="text-align: right;">(3,561)</td>
<td style="text-align: right;">(13,028)</td>
<td style="text-align: right;">(13,721)</td>
<td style="text-align: right;">(27,528)</td>
</tr>
<tr>
<td>Cash from operating activities</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">(20,121)</td>
<td style="text-align: right;">(15,683)</td>
</tr>
<tr>
<td>Capital expenditures (capex)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">62</td>
<td style="text-align: right;">609</td>
</tr>
<tr>
<td>Free cash flow (approx.)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">(20,183)</td>
<td style="text-align: right;">(16,292)</td>
</tr>
<tr>
<td>Basic &amp; diluted EPS (loss per share)</td>
<td style="text-align: right;">0.05</td>
<td style="text-align: right;">0.07</td>
<td style="text-align: right;">0.18</td>
<td style="text-align: right;">3.89</td>
<td style="text-align: right;">3.08</td>
<td style="text-align: right;">1.15</td>
<td style="text-align: right;">1.75</td>
<td style="text-align: right;">1.89</td>
<td style="text-align: right;">0.05</td>
<td style="text-align: right;">2.12</td>
<td style="text-align: right;">0.27</td>
<td style="text-align: right;">4.47</td>
</tr>
<tr>
<td>Total assets</td>
<td style="text-align: right;">17,693</td>
<td style="text-align: right;">6,816</td>
<td style="text-align: right;">11,567</td>
<td style="text-align: right;">8,561</td>
<td style="text-align: right;">10,476</td>
<td style="text-align: right;">12,412</td>
<td style="text-align: right;">17,061</td>
<td style="text-align: right;">24,820</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
</tr>
<tr>
<td>Total non-current financial liabilities</td>
<td style="text-align: right;">18,394</td>
<td style="text-align: right;">18,982</td>
<td style="text-align: right;">18,333</td>
<td style="text-align: right;">61,115</td>
<td style="text-align: right;">57,947</td>
<td style="text-align: right;">56,723</td>
<td style="text-align: right;">23,291</td>
<td style="text-align: right;">53,128</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Source: Conavi MD&amp;A for the three and nine months ended June 30,
2025. All figures are in thousands of Canadian dollars unless noted;
per‑share figures in Canadian dollars.</li>
<li>Revenue mix by period comes from the “Summarized Quarterly
Information” table (8 quarters) and “Results of Operations” for the
3M/9M periods.</li>
<li>Gross profit = Total revenue − Cost of sales.</li>
<li>Operating income (loss) [EBIT] = Gross profit − Operating expenses.
For 3M Jun‑25 and 3M Jun‑24, the computed EBIT ties to the MD&amp;A
“Operating loss.”</li>
<li>EBITDA (only where D&amp;A is provided) = EBIT + Depreciation &amp;
amortization. D&amp;A is disclosed only for the 3M and 9M periods;
EBITDA for other periods is not available (n/a). Adjusted EBITDA was not
reported.</li>
<li>Net finance costs are presented as reported for the 3M and 9M
periods; quarterly detail beyond those periods was not provided
(n/a).</li>
<li>Cash from operating activities, capex, and free cash flow are only
disclosed for the 9M periods. Free cash flow (approx.) = Cash from
operating activities − Capex. 9M FY2025 capex was $62 (PPE); 9M FY2024
capex approximated as $417 (PPE) + $192 (patents) = $609.</li>
<li>Negative cost of sales in Q2‑2025 reflects inventory provision
releases/scrappage adjustments discussed in the MD&amp;A.</li>
<li>EPS in the 3M/9M columns uses the MD&amp;A “Basic and diluted loss
per common share” for those specific comparative periods; quarterly EPS
shown for the last eight quarters is from the quarterly summary.</li>
</ul>
<h2 id="capitalization-cash-debt-and-enterprise-value">Capitalization,
Cash, Debt, and Enterprise Value</h2>
<table>
<thead>
<tr>
<th>Item</th>
<th>Value (CAD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price</td>
<td>$0.65</td>
</tr>
<tr>
<td>Basic Shares</td>
<td>76,750,086</td>
</tr>
<tr>
<td>Fully Diluted Shares (TSM)</td>
<td>97,043,029</td>
</tr>
<tr>
<td>Implied Market Cap (Basic)</td>
<td>$49.9m</td>
</tr>
<tr>
<td>Implied Market Cap (Fully Diluted)</td>
<td>$63.1m</td>
</tr>
<tr>
<td>Cash (6/30/2025)</td>
<td>$11.3m</td>
</tr>
<tr>
<td>Debt (6/30/2025)</td>
<td>$17.9m</td>
</tr>
<tr>
<td>Net Debt</td>
<td>$6.6m</td>
</tr>
<tr>
<td>EV (Basic)</td>
<td>$56.5m</td>
</tr>
<tr>
<td>EV (Fully Diluted)</td>
<td>$69.7m</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Share counts as of Aug 29, 2025 per MD&amp;A:
<ul>
<li>Common shares: 76,750,086 (basic).</li>
<li>Pre-Funded Warrants: 17,500,000 (exercise price $0.00001) treated as
shares for fully diluted.</li>
<li>Stock options: 7,261,652; equity warrants: 18,912,049; most warrants
have US$ strikes ($1.35, $1.08) and are out-of-the-money at $0.65 CAD,
thus excluded from fully diluted.</li>
</ul></li>
<li>Fully diluted shares (treasury stock method, assumptions):
<ul>
<li>Treat all options as in-the-money at an assumed weighted average
strike of $0.40 (consistent with April 2025 offering price and disclosed
compensation option terms).</li>
<li>Option proceeds = 7,261,652 × $0.40 = $2,904,661; shares repurchased
at $0.65 = $2,904,661 / 0.65 = 4,468,709; incremental option shares =
7,261,652 − 4,468,709 = 2,792,943.</li>
<li>Fully diluted = 76,750,086 + 17,500,000 (pre-funded) + 2,792,943
(ITM options TSM) = 97,043,029.</li>
<li>Equity warrants (mainly US$1.35 and US$1.08) are out-of-the-money at
$0.65 CAD (approx. C$1.80 and C$1.45 using ~1.35 FX), excluded. If any
options carry exercise prices above $0.65, our fully diluted count is
conservative/high; if lower, it’s conservative/low—see assumption
above.</li>
</ul></li>
<li>Cash and debt:
<ul>
<li>Cash and equivalents (6/30/2025): $11.283m.</li>
<li>Debt (6/30/2025): $15.441m Japan Lifeline senior secured facility +
$1.704m FedDev repayable contribution + $0.466m SOFII loan + $0.270m
MaRS IAF loan = $17.881m. Lease liabilities exist but period-end balance
not disclosed in MD&amp;A; excluded from EV.</li>
</ul></li>
<li>Market caps:
<ul>
<li>Basic market cap = 76,750,086 × $0.65 = $49.9m.</li>
<li>Fully diluted market cap = 97,043,029 × $0.65 ≈ $63.1m.</li>
</ul></li>
<li>EV:
<ul>
<li>EV = Equity value + Debt − Cash.</li>
<li>EV (Basic) = $49.9m + $17.9m − $11.3m ≈ $56.5m.</li>
<li>EV (FD) = $63.1m + $17.9m − $11.3m ≈ $69.7m.</li>
</ul></li>
<li>Pro‑forma after quarter end: No post‑Q2/2025 financing or share
changes disclosed after June 30, 2025; no pro-forma adjustments
applied.</li>
</ul>
<h2 id="valuation">Valuation</h2>
<table>
<colgroup>
<col style="width: 28%" />
<col style="width: 35%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr>
<th>Metric</th>
<th>Basic</th>
<th>Fully Diluted</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV/EBIT (LTM)</td>
<td>n.m. (negative EBIT)</td>
<td>n.m. (negative EBIT)</td>
</tr>
<tr>
<td>EV/adjusted EBITDA (LTM)</td>
<td>n.m. (negative EBITDA)</td>
<td>n.m. (negative EBITDA)</td>
</tr>
<tr>
<td>EV/unlevered FCF (LTM)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>LTM period = Q4‑2024 through Q3‑2025 (quarters ended Sep‑24, Dec‑24,
Mar‑25, Jun‑25).</li>
<li>EBIT (Operating income) by quarter (CAD ‘000s):
<ul>
<li>Q3‑2025: −4,629; Q2‑2025: −5,407; Q1‑2025: +269; Q4‑2024:
−6,222.</li>
<li>LTM EBIT = −4,629 − 5,407 + 269 − 6,222 = −15,989k.</li>
</ul></li>
<li>EBITDA (CAD ‘000s):
<ul>
<li>D&amp;A disclosed for 3M/9M: 3M Jun‑25 = 203; 9M Jun‑25 total = 613
→ implies Q1+Q2 D&amp;A ≈ 410 (assumed split evenly ≈ 205 each). Q4‑2024
D&amp;A not disclosed; assumed ≈ 249 (avg of 9M‑2024/3).</li>
<li>EBITDA by quarter ≈ EBIT + D&amp;A: Q3‑2025 (−4,629 + 203) = −4,426;
Q2‑2025 (−5,407 + ~205) ≈ −5,202; Q1‑2025 (269 + ~205) ≈ 474; Q4‑2024
(−6,222 + ~249) ≈ −5,973.</li>
<li>LTM EBITDA ≈ −4,426 − 5,202 + 474 − 5,973 = −15,127k.</li>
</ul></li>
<li>Adjusted EBITDA: not disclosed; EBITDA used where applicable; given
negative EBITDA, EV/EBITDA is not meaningful (n.m.).</li>
<li>Unlevered Free Cash Flow (UFCF):
<ul>
<li>Cash from operating activities (CFO) disclosed only for 9M periods:
9M‑2025 CFO = −$20,121k; 9M‑2025 capex = $62k. Q4‑2024 CFO/capex not
disclosed; therefore LTM FCF and LTM UFCF cannot be reliably computed
(n/a).</li>
<li>For reference (not LTM): 9M‑2025 FCF ≈ −$20,121k − $62k = −$20,183k;
9M‑2025 net finance costs = $11,542k; implied 9M‑2025 UFCF ≈ −$8,641k
(illustrative only; not used in multiples).</li>
</ul></li>
<li>All figures in Canadian dollars. Warrants are liability-classified
for accounting but are not debt and are excluded from EV.</li>
</ul>
</body>
</html>
